Sonoma Pharmaceuticals (STU:O8Z3) ROCE % : -30.46% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sonoma Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2023 was -30.46%.

Sonoma Pharmaceuticals ROCE % Historical Data

The historical data trend for Sonoma Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals ROCE % Chart

Sonoma Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-88.80

-34.51

-32.08

-50.93

-36.30

Sonoma Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-65.99	-40.56	-40.48	-43.79	-30.46

Sonoma Pharmaceuticals ROCE % Calculation

Sonoma Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-4.268	/	( ( (17.111 - 5.284)	+	(15.16 - 3.472) )	/ 2 )
	=	-4.268	/	( (11.827	+	11.688)	/ 2 )
	=	-4.268	/	11.7575
	=	-36.30 %

Sonoma Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-3.096	/	( ( (12.776 - 3.035)	+	(13.405 - 2.819) )	/ 2 )
	=	-3.096	/	( ( 9.741	+	10.586 )	/ 2 )
	=	-3.096	/	10.1635
	=	-30.46 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Sonoma Pharmaceuticals (STU:O8Z3) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sonoma Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonoma Pharmaceuticals (STU:O8Z3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z3) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SNOA:USA

Address

5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301

Website

https://www.sonomapharma.com

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Sonoma Pharmaceuticals (STU:O8Z3) Headlines

No Headlines